Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8921348 | CORCEPT THERAP | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists |
Aug, 2028
(4 years from now) | |
US10842801 | CORCEPT THERAP | Optimizing mifepristone absorption |
Nov, 2032
(9 years from now) | |
US10500216 | CORCEPT THERAP | Optimizing mifepristone absorption |
Mar, 2033
(9 years from now) | |
US10660904 | CORCEPT THERAP | Optimizing mifepristone levels for cushing's patients |
Apr, 2036
(12 years from now) | |
US9943526 | CORCEPT THERAP | Optimizing mifepristone levels for cushing's patients |
Apr, 2036
(12 years from now) | |
US10166242 | CORCEPT THERAP | Optimizing mifepristone levels for Cushing's patients |
Apr, 2036
(12 years from now) | |
US10166243 | CORCEPT THERAP | Optimizing mifepristone levels for cushing'S patients |
Apr, 2036
(12 years from now) | |
US10006924 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent cushing's syndrome |
Aug, 2036
(12 years from now) | |
US10495650 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
Aug, 2036
(12 years from now) | |
US9829495 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
Aug, 2036
(12 years from now) | |
US10151763 | CORCEPT THERAP | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome |
Jan, 2037
(13 years from now) | |
US10842800 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(13 years from now) | |
US10195214 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(13 years from now) | |
US10780097 | CORCEPT THERAP | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(14 years from now) | |
US10231983 | CORCEPT THERAP | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(14 years from now) | |
US10314850 | CORCEPT THERAP | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(14 years from now) |
Korlym is owned by Corcept Therap.
Korlym contains Mifepristone.
Korlym has a total of 16 drug patents out of which 0 drug patents have expired.
Korlym was authorised for market use on 17 February, 2012.
Korlym is available in tablet;oral dosage forms.
Korlym can be used as treating cushing's syndrome.
The generics of Korlym are possible to be released after 22 August, 2038.
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic